EFFECTS OF RISPERIDONE DISCONTINUATION IN PATIENTS WITH ALZHEIMER’S DISEASE
This research study will be treating people with Alzheimer’s disease who suffer from: delusions, anxiety and/or sleep problems, agitation, aggression, and hallucinations (e.g. hearing voices). Those who qualify receive treatment with risperidone and memory and thinking tests for at least 16 weeks. For more information please contact Olivia Campa at (310) 478-3711 x42386 or olivia.campa@va.gov.

MEMANTINE TREATMENT AND PET IMAGING IN PATIENTS WITH ALZHEIMER’S DISEASE
This research study will be treating people with a diagnosis of Alzheimer’s disease who are not currently taking memantine (Namenda). The purpose of this research study is to see how treatment with an FDA approved medication, memantine, affects activity in different parts of the brain. All those who qualify will receive treatment with memantine, a MRI and PET scan of the brain, and memory and thinking tests for 1 year. For more information please contact Olivia Campa at (310) 478-3711 x42386 or olivia.campa@va.gov.

BAPINEUZUMAB AS AN ANTI-ALZHEIMER’S THERAPY
This research study will examine the safety and effectiveness of bapineuzumab, an anti-Amyloid Beta antibody, on the progression of Alzheimer’s disease. The study involves 6 intravenous infusions of the investigational drug over the course of 11/2 years. For more information, please call the Kagan Treatment Development Program at (310) 794-6191.